At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Pre-Mkt 12-23 05:42:46 EST
17.62
-0.38
-2.11%
High18.41Low17.41Vol634.13K
Open17.97D1 Closing18.00Amplitude5.58%
Mkt Cap551.33MTradable Cap276.50MTotal Shares31.29M
T/O11.27MT/O Rate4.04%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Is JW (Cayman) Therapeutics (HKG:2126) A Risky Investment?
Simply Wall St.  ·  07:59
Is JW (Cayman) Therapeutics (HKG:2126) A Risky Investment?
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
GlobeNewswire  ·  12-22 23:15
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Ovid Therapeutics Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Dow Jones  ·  12-22 19:43
Ovid Therapeutics Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
GlobeNewswire  ·  12-22 19:29
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
Outlook Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  12-22 18:50
Outlook Therapeutics Is Maintained at Buy by Ascendiant Capital
Qyuns Therapeutics Sells QX027N Drug License to LE2025 Therapeutics
MT Newswires Live  ·  12-22 09:50
Qyuns Therapeutics Sells QX027N Drug License to LE2025 Therapeutics
Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  12-19
Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
CARsgen Therapeutics Holdings (SEHK:2171): Valuation Check After Zevor‑cel Listing and New CT0596 Data
Simply Wall St.  ·  12-19
CARsgen Therapeutics Holdings (SEHK:2171): Valuation Check After Zevor‑cel Listing and New CT0596 Data
CARsgen Therapeutics Extends Share Repurchase Program
MT Newswires Live  ·  12-19
CARsgen Therapeutics Extends Share Repurchase Program
Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm
MT Newswires Live  ·  12-19
Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm
PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study
MT Newswires Live  ·  12-19
PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
GlobeNewswire  ·  12-18
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
GlobeNewswire  ·  12-18
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Piper Sandler Initiates Coverage on Oruka Therapeutics With Overweight Rating
MT Newswires Live  ·  12-18
Piper Sandler Initiates Coverage on Oruka Therapeutics With Overweight Rating
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
GlobeNewswire  ·  12-18
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
GlobeNewswire  ·  12-18
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
GlobeNewswire  ·  12-18
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target
MT Newswires Live  ·  12-18
Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
GlobeNewswire  ·  12-18
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Vistagen Therapeutics Cut to Hold From Buy by Jefferies
Dow Jones  ·  12-18
Vistagen Therapeutics Cut to Hold From Buy by Jefferies

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--